Article Text

Download PDFPDF
Letter
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma
  1. Ning Lyu1,
  2. Youen Lin2,
  3. Yanan Kong3,
  4. Zhenfeng Zhang1,
  5. Longzhong Liu1,
  6. Lie Zheng1,
  7. Luwen Mu1,
  8. Jianpeng Wang4,
  9. Xishan Li5,
  10. Tao Pan1,
  11. Qiankun Xie1,
  12. Yaru Liu1,
  13. Aihua Lin6,
  14. Peihong Wu1,
  15. Ming Zhao1
  1. 1 Division of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China
  2. 2 Department of Interventional Radiology, Jieyang Affiliated Hospital, Sun Yat-sen University, Jieyang, China
  3. 3 State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
  4. 4 Department of Minimally Invasive Interventional and Target Treatment, Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, China
  5. 5 Department of Interventional Radiology, First People’s Hospital, Guangzhou, China
  6. 6 Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China
  1. Correspondence to Ming Zhao, Minimally Invasive Interventional Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China; drmingzhao{at}outlook.com

Statistics from Altmetric.com

We read with interest the article of recent advances in clinical practice of hepatocellular carcinoma (HCC) treatment by Bruix et al in Gut. 1 In this review, the Barcelona Clinic Liver Cancer (BCLC) Group recommended sorafenib as the standard treatment for BCLC-C stage (advanced stage) HCC. However, application of sorafenib as first treatment for advanced HCC worldwide was low according to a multiregional, large-scale, longitudinal cohort study.2 This may be attributed to some limitations of sorafenib: low response rate, modest survival advantage, complex mechanism underlying acquired resistance and high-level heterogeneity of individual response.3 4 Recently, evidence from an individual patient data meta-analysis of phase III randomised controlled trial showed no improvement in overall survival attributable to sorafenib for HBV-related HCC.5 Therefore, more alternative strategies are highly required.6

Hepatic arterial infusion (HAI) chemotherapy (HAIC) attracted more attentions in recent years due to high response rates and …

View Full Text

Footnotes

  • NL, YL and YK contributed equally.

  • Contributors MZ, NL, YoL, and YK conceived and designed the study. NL, YoL, ZZ, LL, LZ, LM, YL, QX, TP, JW and XL collected the data. NL, YK, AL, PW and MZ analysed and interpreted the data. All authors were involved in the drafting, review and approval of the report and the decision to submit for publication.

  • Competing interests None declared.

  • Ethics approval The Ethical Review Committee of Sun Yat-sen University Cancer Center.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.